Clinical trial · no report yet · Phase 2
InTRist
Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC
- NCT05888402 ↗
- Active, not recruiting
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 33 |
The trial
ClinicalTrials.gov- Official title
- The Efficacy and Safety of Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume (Bulky) Local Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Local Advanced Non-small Cell Lung Cancer
- Interventions
- Toripalimab; Concurrent chemoradiation therapy and consolidation immunotherapy
- Arms
- Induction Toripalimab and chemotherapy followed by concurrent chemoradiotherapy · Experimental
- Induction chemotherapy followed by concurrent chemoradiotherapy · Active comparator
- Enrollment
- 50 (estimated)
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences with Shanghai Junshi Bioscience Co., Ltd.
- Start
- Jan 20, 2023
- Primary completion
- Oct 8, 2024
- Results posted
- No
- Registry record
- NCT05888402 · updated Feb 27, 2026
Publications
linked from the registry- Wang Y, Deng L, Wang J, Zhang T, Wang W, Wang X, Liu W, Wu Y, Lv J, Feng Q, Zhou Z, Wang J, Wang L, Wang Z, Bi N. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study). Front Immunol. 2024 Jan 15;14:1341584. doi: 10.3389/fimmu.2023.1341584. eCollection 2023. PubMed 38288117